Placebo + Lemborexant 10 mg + Lemborexant 25 mg + Placebo + Lemborexant 10 mg
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Sleep Apnea
Conditions
Obstructive Sleep Apnea, Healthy Subjects
Trial Timeline
Feb 21, 2018 → Aug 3, 2018
NCT ID
NCT03471871About Placebo + Lemborexant 10 mg + Lemborexant 25 mg + Placebo + Lemborexant 10 mg
Placebo + Lemborexant 10 mg + Lemborexant 25 mg + Placebo + Lemborexant 10 mg is a phase 1 stage product being developed by Eisai for Obstructive Sleep Apnea. The current trial status is completed. This product is registered under clinical trial identifier NCT03471871. Target conditions include Obstructive Sleep Apnea, Healthy Subjects.
What happened to similar drugs?
20 of 20 similar drugs in Obstructive Sleep Apnea were approved
Approved (20) Terminated (2) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03471871 | Phase 1 | Completed |
Competing Products
20 competing products in Obstructive Sleep Apnea